Third Harmonic Bio, Inc.
THRDDelisted- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001923840
Third Harmonic Bio, Inc. was delisted in 2025; its insiders filed their last Form 4 on Aug 14, 2025; 107 institutions reported holding it in 13F filings for Q2 2025, worth $210.3M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 107
- Q2 2025, +7 vs. previous quarter
- 13F value
- $210.2M
- Reported value at the end of Q2 2025
- Superinvestors holding
- 0
- At the end of Q2 2025
Superinvestors holding THRD, Q2 2025
No superinvestor reported holding THRD at the end of Q2 2025.
Latest insider trades
Open-market purchases and sales by Third Harmonic Bio, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 12, 2024 (view filing) | Nov 8 | 4 days | Conner Edward R.Chief Medical Officer | SSale | −2.12K | $15.00 | −$31.8K | −100.0%0 after | 10b5-1 |
| Oct 31, 2024 (view filing)5:53 PM ET | Oct 29 | 2 days | Biotechnology Value Fund L P and 9 othersOther: See Explanation of Responses | SSale | −1.00M | $14.30 | −$14.3M | −85.0%176.7K after | 3 lots |
| Oct 30, 2024 (view filing) | Oct 28 | 2 days | Conner Edward R.Chief Medical Officer | SSale | −2.67K | $15.00 | −$40.1K | −100.0%0 after | 10b5-1 |
| Sep 20, 2024 (view filing) | Sep 19 | 1 day | Conner Edward R.Chief Medical Officer | SSale | −4.79K | $15.00 | −$71.8K | −100.0%0 after | 10b5-1 |
| Sep 20, 2024 (view filing) | Sep 18-19 | 2 days | Person JulieCHIEF ADMINISTRATIVE OFFICER | SSale | −10.0K | $14.28 | −$142.8K | −100.0%0 after | 2 lots10b5-1 |
| Jun 28, 2024 (view filing) | Jun 26 | 2 days | Person JulieCHIEF ADMINISTRATIVE OFFICER | SSale | −10.0K | $12.46 | −$124.6K | −100.0%0 after | 10b5-1 |
| Jun 10, 2024 (view filing) | Jun 7 | 3 days | Dittman JenniferChief Development Oper Officer | SSale | −494 | $14.17 | −$7.00K | −100.0%0 after | 10b5-1 |
| May 22, 2024 (view filing) | May 20 | 2 days | Dittman JenniferChief Development Oper Officer | SSale | −1.04K | $14.00 | −$14.6K | −100.0%0 after | 10b5-1 |
| May 20, 2024 (view filing) | May 16 | 4 days | Dittman JenniferChief Development Oper Officer | SSale | −23.6K | $14.04 | −$331.0K | −100.0%0 after | 10b5-1 |
| May 10, 2024 (view filing) | May 9 | 1 day | Holles Natalie C.CEO | SSale | −20.2K | $12.18 | −$246.3K | −1.6%1.22M after | 10b5-1 |
Top 10 13F holders, Q2 2025
The largest institutional positions in Third Harmonic Bio, Inc. at the end of Q2 2025; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Atlas Venture Life Science Advisors, LLC | 10,402,286 | $56.5M | 8.53% | 00.0% | Unchanged |
| OrbiMed Advisors LLC | 5,779,071 | $31.4M | 0.79% | 00.0% | Unchanged |
| BML Capital Management, LLC | 3,824,417 | $20.8M | 15.91% | 00.0% | Unchanged |
| Nantahala Capital Management, LLC | 2,938,700 | $16.0M | 1.13% | 00.0% | Unchanged |
| TCG Crossover Management, LLC | 1,915,424 | $10.4M | 1.19% | −590,000−23.5% | Reduced |
| BlackRock, Inc. | 1,726,614 | $9.38M | 0.00% | +246,996+16.7% | Added |
| Vanguard Group Inc | 1,298,089 | $7.05M | 0.00% | +138,489+11.9% | Added |
| D. E. Shaw & Co., Inc. | 1,250,680 | $6.79M | 0.01% | +677,346+118.1% | Added |
| Tang Capital Management LLC | 929,727 | $5.05M | 0.26% | 00.0% | Unchanged |
| Schonfeld Strategic Advisors LLC | 770,800 | $4.19M | 0.03% | +740,694+2,460.3% | Added |